Emerging treatments in COVID-19: Adverse drug reactions including drug hypersensitivities
JournalItem (Reviews, Editorials, Rezensionen, Urteilsanmerkungen etc. in einer wissenschaftlichen Zeitschrift)
ID
4600886
Author(s)
Manjaly Thomas, Zita-Rose; Leuppi-Taegtmeyer, Anne; Jamiolkowski, Dagmar; Steveling-Klein, Esther; Bellutti-Enders, Felicitas; Scherer Hofmeier, Kathrin; Hartmann, Karin
Author(s) at UniBasel
Hartmann, Karin Manjaly Thomas, Zita-Rose Steveling-Klein, Esther Helen
Year
2020
Title
Emerging treatments in COVID-19: Adverse drug reactions including drug hypersensitivities
Journal
Journal Of Allergy And Clinical Immunology
Volume
146
Number
4
Pages
786-789
Keywords
Acute respiratory syndrome; COVID-19; SARS-CoV-2; adverse drug reactions; coronavirus; drug allergy; drug hypersensitivity; remdesivir
Mesh terms
Adenosine Monophosphate, analogs & derivatives; Adrenal Cortex Hormones, therapeutic use; Alanine, analogs & derivatives; Amides, adverse effects; Antibodies, Monoclonal, Humanized, adverse effects; Antiviral Agents, adverse effects; Betacoronavirus, pathogenicity; COVID-19; Coronavirus Infections, virology; Cytokine Release Syndrome, virology; Drug Hypersensitivity, immunology; Humans; Immunity, Innate, drug effects; Immunologic Factors, adverse effects; Indoles, adverse effects; Infliximab, adverse effects; Interleukin 1 Receptor Antagonist Protein, adverse effects; Pandemics; Pneumonia, Viral, virology; Pyrazines, adverse effects; Pyrazoles, adverse effects; SARS-CoV-2; Severity of Illness Index
Publisher
Mosby
ISSN/ISBN
0091-6749 ; 1097-6825
edoc-URL
https://edoc.unibas.ch/77919/
Full Text on edoc
No
Digital Object Identifier DOI
10.1016/j.jaci.2020.07.008
PubMed ID
http://www.ncbi.nlm.nih.gov/pubmed/32710973
ISI-Number
WOS:000582395800008
Document type (ISI)
Editorial, Review
MCSS v5.8 PRO. 0.350 sec, queries - 0.000 sec
©Universität Basel | Impressum
|
29/04/2024
Research Database / FORSCHUNGSDATENBANK
